Predictors of genetic testing uptake in newly diagnosed breast cancer patients

Many newly diagnosed breast cancer patients do not receive genetic counseling and testing at the time of diagnosis. We examined predictors of genetic testing (GT) in this population.

[1]  H. Valdimarsdottir,et al.  Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients , 2020, Breast Cancer Research and Treatment.

[2]  R. Tollenaar,et al.  Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. , 2019, Annals of surgery.

[3]  Judy C. Boughey,et al.  Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons , 2019, Annals of Surgical Oncology.

[4]  Megan C. Roberts,et al.  Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey , 2019, Journal of personalized medicine.

[5]  N. Magné,et al.  Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view. , 2019, The British journal of radiology.

[6]  Rakesh R. Patel,et al.  Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Isaacs,et al.  Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. , 2018, Translational behavioral medicine.

[8]  H. Valdimarsdottir,et al.  Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients , 2018, Breast Cancer Research and Treatment.

[9]  C. Eng,et al.  Impact of an embedded genetic counselor on breast cancer treatment , 2018, Breast Cancer Research and Treatment.

[10]  L. Senter,et al.  Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. , 2017, Gynecologic oncology.

[11]  J. Garber,et al.  Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up , 2017, JNCI cancer spectrum.

[12]  Robert Huether,et al.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer , 2017, JAMA oncology.

[13]  C. Childers,et al.  National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Munsell,et al.  A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. , 2017, Gynecologic oncology.

[15]  D. Zakalik,et al.  Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis , 2017, Hereditary Cancer in Clinical Practice.

[16]  N. Morman,et al.  Barriers to genetic testing in newly diagnosed breast cancer patients: Do surgeons limit testing? , 2017, American journal of surgery.

[17]  A. Jemal,et al.  State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012 , 2017, JAMA surgery.

[18]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[19]  R. Jagsi,et al.  Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer , 2017, JAMA.

[20]  R. Jagsi,et al.  Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer , 2016, JAMA surgery.

[21]  E. Winer,et al.  Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Couch,et al.  Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer , 2016, Annals of Surgical Oncology.

[23]  R. Tamimi,et al.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. , 2016, JAMA oncology.

[24]  T. Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[25]  Claudia X. Aguado Loi,et al.  Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study. , 2015, JAMA oncology.

[26]  M. King,et al.  Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. , 2014, JAMA.

[27]  C. Raker,et al.  Preoperative genetic testing affects surgical decision making in breast cancer patients. , 2014, Gynecologic oncology.

[28]  Elizabeth C. Chao,et al.  The Validation and Clinical Implementation of BRCAplus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay , 2014, PloS one.

[29]  J. Garber,et al.  Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  W. Foulkes,et al.  Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis , 2014, BMJ : British Medical Journal.

[31]  E. Rutgers,et al.  Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. , 2013, Breast.

[32]  J. Harvey,et al.  Breast cancer—facts and figures , 2013 .

[33]  H. Valdimarsdottir,et al.  Intentions for bilateral mastectomy among newly diagnosed breast cancer patients , 2013, Journal of surgical oncology.

[34]  E. Hoodfar,et al.  Does the Diagnosis of Breast or Ovarian Cancer Trigger Referral to Genetic Counseling? , 2013, International Journal of Gynecologic Cancer.

[35]  C. Isaacs,et al.  Long-Term Psychosocial Outcomes of BRCA1/BRCA2 Testing: Differences across Affected Status and Risk-Reducing Surgery Choice , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[36]  A. Laenkholm,et al.  Breast cancer after bilateral risk‐reducing mastectomy , 2011, Clinical genetics.

[37]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[38]  A. Howell,et al.  Risk reducing mastectomy: outcomes in 10 European centres , 2008, Journal of Medical Genetics.

[39]  A. Howell,et al.  Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[40]  C. Isaacs,et al.  Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer Patients , 2005, Cancer Epidemiology Biomarkers & Prevention.

[41]  C. Magnant,et al.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Weitzel,et al.  Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. , 2003, Archives of surgery.

[43]  R. Grol,et al.  Patient characteristics as predictors of primary health care preferences: a systematic literature analysis , 2003, Health expectations : an international journal of public participation in health care and health policy.

[44]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. O'Connor.  Validation of a Decisional Conflict Scale , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[46]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Derogatis,et al.  The Brief Symptom Inventory: an introductory report , 1983, Psychological Medicine.

[48]  M. Horowitz,et al.  Impact of Event Scale: A Measure of Subjective Stress , 1979, Psychosomatic medicine.

[49]  W. Barry,et al.  Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. , 2016, Annals of surgery.

[50]  D. Penson,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.

[51]  Suzanne O'Neill,et al.  Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. , 2009, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.